Leslie Titus Bryant
March 07, 2023
Spectrum Solutions’ offerings enhanced by including CLIA/CAP laboratory testing, custom assay development, and manufacturing of industry-leading microarray chip technology.
SALT LAKE CITY, UTAH—Spectrum Solutions® today announced the acquisitions of Alimetrix, Inc., a CLIA and CAP accredited molecular diagnostic laboratory skilled at custom qualitative and quantitative assay development, and Microarrays, Inc., a leader in customer array-based products that are used as biological research tools – gene expression arrays, reverse and forward phase protein arrays.
These valuable assets, combined with Spectrum Solutions core competencies of providing industry-leading contract manufacturing services and unique biospecimen collection devices, creates a unique synergistic relationship resulting in a portfolio of products and services that enhances the overall patient testing experience whether in a clinical setting or at home. Alimetrix, Inc.’s molecular laboratory capabilities and Microarrays, Inc.’s expertise in manufacturing array-based products, now coupled with Spectrum’s capabilities creates a comprehensive suite of products and services accelerating Spectrum’s go-to-market strategies.
Spectrum’s core business divisions include:
- Spectrum LabServices™, including innovative assay development, contract manufacturing, and clinical testing business support services.
- Spectrum SimplyTest™, a family of validated, highly sensitive multiplex laboratory-developed tests for both direct-to-consumer and physician-directed testing.
- Spectrum Compounding RX™ Pharmacy, an onsite, multi-state licensed patient-specific compounding pharmacy partner with direct-to-patient dispensing capabilities.
“The acquisitions of Alimetrix and Microarrays not only enhances Spectrum’s portfolio to include high-impact laboratory testing and custom assay services, it also serves to advance patient care and clinical research,” said Stephen Fanning, CEO at Spectrum Solutions. “Spectrum is now one step closer to its vision of developing a transformative, decentralized healthcare platform aimed at innovating the way biospecimens are collected and laboratory testing is conducted.”
“At Alimetrix and Microarrays, our mission has always been dedicated to performing work bigger than ourselves that enables positive change in the world through science. Joining forces with a scientifically committed company like Spectrum will extend and enhance our capabilities to the masses and help individuals and communities take control of their health,” said Joel Peek, President and Chief Science Officer at Alimetrix and Microarrays.
Click here to view this press release on the Business Wire.